Search details
1.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 389(6): 504-513, 2023 Aug 10.
Article
in English
| MEDLINE | ID: mdl-37379158
2.
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Br J Cancer
; 130(3): 417-424, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38097741
3.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol
; 23(6): 781-792, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35576957
4.
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
BMC Cancer
; 22(1): 732, 2022 Jul 05.
Article
in English
| MEDLINE | ID: mdl-35790916
5.
Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
N Engl J Med
; 389(16): 1534-1535, 2023 Oct 19.
Article
in English
| MEDLINE | ID: mdl-37851886
6.
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
BMC Cancer
; 21(1): 977, 2021 Aug 31.
Article
in English
| MEDLINE | ID: mdl-34465283
7.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(11): 1413-1422, 2020 11.
Article
in English
| MEDLINE | ID: mdl-32979984
8.
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.
Cancer Immunol Immunother
; 68(3): 341-352, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30725206
9.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(7): 789-96, 2016 09 27.
Article
in English
| MEDLINE | ID: mdl-27599039
10.
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.
BMC Cancer
; 16: 312, 2016 05 14.
Article
in English
| MEDLINE | ID: mdl-27179511
11.
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
BMC Cancer
; 15: 327, 2015 Apr 29.
Article
in English
| MEDLINE | ID: mdl-25925749
12.
Difficulties on the access to innovative targeted therapies for lung cancer in Spain.
Clin Transl Oncol
; 26(3): 597-612, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37651020
13.
Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.
Clin Transl Oncol
; 2024 Jun 11.
Article
in English
| MEDLINE | ID: mdl-38862862
14.
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Lung Cancer
; 192: 107820, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38763104
15.
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Clin Transl Oncol
; 2024 Apr 05.
Article
in English
| MEDLINE | ID: mdl-38578537
16.
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
Lung Cancer
; 190: 107513, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38432027
17.
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.
Arch Bronconeumol
; 60(2): 88-94, 2024 Feb.
Article
in English, Spanish
| MEDLINE | ID: mdl-38160163
18.
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
Clin Cancer Res
; 2024 Apr 17.
Article
in English
| MEDLINE | ID: mdl-38630755
19.
RET Fusion Testing in Patients With NSCLC: The RETING Study.
JTO Clin Res Rep
; 5(4): 100653, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38525319
20.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Clin Transl Oncol
; 26(7): 1779-1789, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38512450